Thrombosis and Cancer Immunotherapy: The Next Frontier of Thromboinflammation

Introduction

Cancer treatment has undergone a major transformation with the advent of immunotherapy, a therapeutic approach designed to harness the patient’s immune system to recognize and eliminate malignant cells. Immune checkpoint inhibitors, chimeric antigen receptor T cell therapies, cancer vaccines, and other immunomodulatory strategies have significantly improved outcomes across multiple malignancies, including melanoma, lung cancer, renal cell carcinoma, and hematologic cancers. Despite these advances, immune activation also introduces complex systemic effects that extend beyond tumor control, including profound interactions with coagulation and inflammatory pathways.

The association between cancer and thrombosis has been recognized for more than 150 years, dating back to Armand Trousseau’s observations linking migratory thrombophlebitis with occult malignancy. Since then, cancer associated thrombosis has become well established as a major contributor to morbidity and mortality among oncology patients. Malignancy promotes a hypercoagulable state through multiple mechanisms, including tumor cell expression of tissue factor, platelet activation, endothelial dysfunction, cytokine release, and disruption of normal hemostatic balance. However, the introduction of immunotherapy has added new dimensions to this already complex relationship by intensifying immune mediated inflammatory responses that can further influence coagulation pathways.

The concept of thromboinflammation has emerged as a critical framework for understanding these interactions. Thromboinflammation refers to the bidirectional relationship between inflammation and thrombosis, in which immune activation promotes coagulation while coagulation pathways amplify inflammatory signaling. In patients receiving cancer immunotherapy, this interplay becomes particularly significant because therapeutic immune stimulation may inadvertently trigger prothrombotic processes. Activation of T cells, macrophages, neutrophils, and inflammatory cytokine cascades can alter endothelial integrity, increase platelet reactivity, and enhance thrombin generation, thereby predisposing patients to both venous and arterial thrombotic events.

This issue carries substantial clinical relevance given the high baseline thrombotic risk in cancer populations. The incidence of thrombotic events in oncology patients is estimated to range between 15 and 20 percent, making thrombosis one of the leading causes of death in individuals with cancer outside of disease progression itself. Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, represents the most common manifestation, although arterial events such as myocardial infarction and ischemic stroke are increasingly recognized in certain treatment contexts. As immunotherapy becomes more widely integrated into standard oncologic care, emerging evidence suggests that novel patterns of thrombotic complications may be associated with these agents.

Immune checkpoint inhibitors, particularly those targeting programmed cell death protein 1, programmed death ligand 1, and cytotoxic T lymphocyte associated antigen 4 pathways, have been linked to inflammatory vascular complications and coagulation abnormalities in several observational studies. Proposed mechanisms include endothelial activation, cytokine mediated vascular injury, autoimmune vasculitis, and dysregulated immune cell interactions with platelets and coagulation factors. In addition, immunotherapy related adverse events involving multiple organ systems may indirectly contribute to thrombosis through immobilization, systemic inflammation, corticosteroid exposure, and hospitalization.

Neutrophil extracellular traps have also gained attention as important mediators of thromboinflammation in cancer immunotherapy. These extracellular DNA structures, released by activated neutrophils, can promote clot formation by serving as scaffolds for platelets and coagulation proteins. Increased neutrophil extracellular trap formation has been implicated in both tumor progression and thrombotic complications, highlighting another potential mechanistic link between immune activation and coagulation dysregulation.

The clinical consequences of thromboinflammatory complications are substantial. Thrombotic events can interrupt cancer treatment, increase hospitalization rates, impair quality of life, and worsen overall survival. Moreover, anticoagulation management in oncology patients remains challenging due to concurrent bleeding risk, drug interactions, thrombocytopenia, and procedural considerations. The addition of immunotherapy related inflammatory toxicity further complicates clinical decision making regarding thromboprophylaxis and long term anticoagulation strategies.

Risk stratification therefore represents an increasingly important aspect of modern oncologic care. Traditional predictive tools such as the Khorana score may not fully capture the unique thrombotic risk associated with immunotherapy. Consequently, researchers are exploring novel biomarkers and inflammatory indices that may better identify patients at highest risk for thromboinflammatory complications. These include circulating cytokine profiles, markers of endothelial dysfunction, platelet activation parameters, and neutrophil extracellular trap associated biomarkers.

Therapeutically, growing interest exists in targeting the intersection of inflammation and coagulation to improve patient outcomes. Anti inflammatory agents, cytokine modulation, and therapies directed at platelet immune interactions are being investigated alongside conventional anticoagulation approaches. At the same time, clinicians must balance thrombosis prevention with preservation of antitumor immune responses, as excessive immunosuppression could potentially diminish treatment efficacy.

As the use of immunotherapy continues to expand across cancer types and disease stages, understanding the mechanisms underlying thromboinflammation has become increasingly essential for oncologists, hematologists, and multidisciplinary cancer care teams. Recognition of these interactions may improve early identification of high risk patients, optimize supportive care strategies, and reduce treatment related complications. Ultimately, integrating thromboinflammatory principles into cancer management represents an important step toward more precise and comprehensive care in the evolving era of cancer immunotherapy.

Historical Context and Evolution

The link between cancer and thrombosis was first described by Armand Trousseau in 1865. He observed that cancer patients often developed blood clots before their cancer diagnosis became apparent. This observation led to the term “Trousseau syndrome,” which describes the tendency for cancer patients to develop thrombotic events.

Traditional cancer treatments like chemotherapy and radiation have well-documented effects on blood clotting. Chemotherapy can damage blood vessels and affect platelet function. Radiation can cause inflammation in blood vessels. However, immunotherapy presents different challenges because it works through immune system activation rather than direct cell destruction.

The first immune checkpoint inhibitor, ipilimumab, was approved in 2011. Since then, numerous immunotherapy agents have been developed, including PD-1 inhibitors, PD-L1 inhibitors, and CAR-T cell therapies. Each of these treatments has unique effects on the immune system and potentially on blood clotting mechanisms.

Molecular Mechanisms of Thromboinflammation

Immune Activation and Coagulation

When immunotherapy activates the immune system, it triggers a cascade of events that can affect blood clotting. T cells, B cells, and other immune cells release cytokines and other inflammatory molecules. These molecules can activate endothelial cells that line blood vessels, making them more prone to clot formation.

Neutrophils play a particularly important role in thromboinflammation. When activated by immunotherapy, neutrophils can release neutrophil extracellular traps (NETs). These web-like structures contain DNA, histones, and enzymes that can trap bacteria, but they also provide a framework for blood clot formation.

Complement System Activation

The complement system is part of the immune system that helps clear damaged cells and pathogens. Immunotherapy can activate the complement system, which then interacts with blood clotting factors. Complement proteins can directly activate platelets and promote clot formation. This interaction between complement and coagulation represents a key mechanism in thromboinflammation.

Cytokine Storm and Coagulation

Some immunotherapy treatments can cause excessive cytokine release, known as cytokine release syndrome. This condition involves high levels of inflammatory molecules like interleukin-6, tumor necrosis factor-alpha, and interferon-gamma. These cytokines can affect blood clotting by activating endothelial cells, promoting tissue factor expression, and altering the balance between pro-coagulant and anticoagulant factors.

Types of Immunotherapy and Thrombotic Risk

Immune Checkpoint Inhibitors

Immune checkpoint inhibitors block proteins that normally prevent excessive immune activation. The most commonly used checkpoint inhibitors target PD-1, PD-L1, and CTLA-4 pathways. These drugs have shown remarkable success in treating various cancers, but they can also cause immune-related adverse events.

Studies have shown that checkpoint inhibitors can increase the risk of arterial thrombotic events, including heart attacks and strokes. The mechanism appears to involve accelerated atherosclerosis due to immune activation. Patients with existing cardiovascular risk factors may be particularly vulnerable to these complications.

Venous thromboembolism risk with checkpoint inhibitors appears to be lower than with traditional chemotherapy, but the data is still evolving. Some studies suggest that the overall thrombotic risk may be similar to chemotherapy, but the types of thrombotic events may differ.

CAR-T Cell Therapy

Chimeric antigen receptor T-cell (CAR-T) therapy involves genetically modifying a patient’s T cells to better recognize and attack cancer cells. This treatment can cause severe immune activation, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS).

CAR-T therapy has been associated with various coagulation abnormalities. Patients may develop low platelet counts, abnormal clotting studies, and increased risk of bleeding or clotting. The cytokine release associated with CAR-T therapy can activate the coagulation cascade and consume clotting factors.

Tumor Vaccines and Immune Modulators

Other forms of immunotherapy, including tumor vaccines and immune modulators like interferons and interleukins, can also affect blood clotting. Interferon therapy has been associated with thrombotic microangiopathy, a condition involving small vessel clots and organ damage.

Clinical Manifestations

Venous Thromboembolism

Venous thromboembolism includes deep vein thrombosis and pulmonary embolism. In cancer patients receiving immunotherapy, these events can present with typical symptoms like leg swelling, chest pain, and shortness of breath. However, the clinical presentation may be complicated by other treatment-related side effects.

The timing of thrombotic events in relation to immunotherapy administration varies. Some patients develop clots within days of starting treatment, while others may develop them weeks or months later. The relationship between treatment cycles and thrombotic risk is still being studied.

Arterial Thrombosis

Arterial thrombotic events include heart attacks, strokes, and peripheral arterial occlusion. These events may be more common with certain types of immunotherapy, particularly in patients with existing cardiovascular risk factors. The presentation of arterial thrombosis in cancer patients may be atypical due to underlying disease and concurrent medications.

Unusual Thrombotic Presentations

Immunotherapy can cause unusual thrombotic presentations that are rarely seen with traditional cancer treatments. These include cerebral venous sinus thrombosis, retinal vein occlusion, and thrombosis in unusual locations. Physicians need to maintain a high index of suspicion for these rare but potentially serious complications.

Risk Factors and Patient Assessment

Traditional Risk Factors

Cancer patients have multiple risk factors for thrombosis even before considering immunotherapy effects. These include the cancer itself, immobility, surgery, central venous catheters, and concurrent medications. Age, obesity, and previous thrombotic events also increase risk.

Immunotherapy-Specific Risk Factors

Certain factors may specifically increase thrombotic risk in patients receiving immunotherapy. These include the type of immunotherapy, dose and schedule, combination with other treatments, and the development of immune-related adverse events. Patients who develop severe cytokine release syndrome or other serious immune-related complications may have higher thrombotic risk.

Laboratory Markers

Various laboratory markers may help identify patients at increased thrombotic risk. D-dimer levels are often elevated in cancer patients and may increase further with immunotherapy. Inflammatory markers like C-reactive protein and interleukin-6 may also predict thrombotic risk. However, these markers are not specific and must be interpreted in clinical context.

Table 1: Thrombotic Risk Factors in Cancer Immunotherapy Patients

Risk Factor Category	Specific Factors	Risk Level
Patient Factors	Age >65 years, BMI >30, Previous VTE	High
Cancer Factors	Advanced stage, Brain metastases, Adenocarcinoma	High
Treatment Factors	Combination therapy, High-dose steroids	Moderate
Laboratory Factors	Elevated D-dimer, Low platelets, High CRP	Moderate
Comorbidities	Heart disease, Diabetes, Kidney disease	High

Diagnostic Challenges

Diagnosing thrombotic events in cancer patients receiving immunotherapy can be challenging for several reasons. Symptoms of thrombosis may overlap with treatment-related side effects. For example, shortness of breath could indicate pulmonary embolism, but it could also be due to immune-related pneumonitis or cardiac toxicity.

Imaging studies may be complicated by the presence of tumor masses or treatment-related changes. Contrast-enhanced CT scans may show abnormalities that are difficult to interpret in the setting of ongoing cancer treatment. Nuclear medicine studies may be affected by immune activation or concurrent medications.

Laboratory tests for thrombosis, such as D-dimer, are often elevated in cancer patients regardless of whether they have blood clots. This makes these tests less useful for diagnosis in this population. Physicians must rely more heavily on clinical judgment and imaging studies.

Management Strategies

Prophylaxis

Preventing thrombotic events in cancer patients receiving immunotherapy requires a careful balance of benefits and risks. Anticoagulant medications can prevent clots but may increase bleeding risk, particularly in patients with low platelet counts or those undergoing procedures.

Current guidelines for thrombosis prevention in cancer patients were developed before the widespread use of immunotherapy. These guidelines may not fully address the unique risks associated with immune activation. New approaches to prophylaxis may be needed for high-risk patients receiving immunotherapy.

Mechanical methods of prevention, such as compression stockings and intermittent pneumatic compression, can be useful adjuncts to pharmacologic prophylaxis. Early mobilization and adequate hydration are also important preventive measures.

Acute Treatment

When thrombotic events occur in patients receiving immunotherapy, treatment must be individualized based on the severity of the event, bleeding risk, and ongoing cancer treatment plans. Standard anticoagulation protocols may need modification in patients with immune-related complications.

Direct oral anticoagulants (DOACs) have become increasingly popular for treating thrombosis in cancer patients. However, their use in patients receiving immunotherapy may be complicated by drug interactions, gastrointestinal side effects, or the need for frequent procedures.

Low molecular weight heparin remains the preferred treatment for many cancer patients with thrombosis. This medication can be given subcutaneously and does not require frequent laboratory monitoring. However, patients with severe kidney dysfunction or very low platelet counts may not be suitable candidates.

Treatment Modifications

When thrombotic events occur during immunotherapy, physicians must decide whether to continue, modify, or discontinue treatment. This decision depends on the severity of the thrombotic event, the response to cancer treatment, and the availability of alternative therapies.

Temporary treatment interruptions may be appropriate while acute thrombotic events are being managed. Some patients may be able to resume immunotherapy once they are stable on anticoagulation. Others may require permanent discontinuation due to high thrombotic risk.

Special Populations

Elderly Patients

Elderly cancer patients face particular challenges when receiving immunotherapy. They have higher baseline thrombotic risk due to age-related changes in blood vessels and clotting factors. They may also have more comorbidities that increase both thrombotic and bleeding risk.

Immune function changes with aging, which may affect both cancer response and side effects from immunotherapy. Elderly patients may be more susceptible to severe immune-related adverse events, including those that increase thrombotic risk.

Patients with Cardiovascular Disease

Cancer patients with existing cardiovascular disease face increased risk of arterial thrombotic events when receiving immunotherapy. Checkpoint inhibitors may accelerate atherosclerosis and increase the risk of heart attacks and strokes in these patients.

Careful coordination between oncologists and cardiologists is essential for these high-risk patients. Some may benefit from more aggressive cardiovascular risk factor modification before starting immunotherapy. Others may require prophylactic antiplatelet therapy or anticoagulation.

Patients with Previous Thrombosis

Patients with a history of thrombotic events have a high risk of recurrence, particularly during cancer treatment. The addition of immunotherapy may further increase this risk through immune activation and inflammatory mechanisms.

These patients often require long-term anticoagulation, which must be carefully managed during cancer treatment. The choice of anticoagulant and monitoring strategy may need modification based on the type of immunotherapy and other concurrent treatments.

Emerging Therapeutic Approaches

Targeted Anti-Inflammatory Therapy

New approaches to managing thromboinflammation focus on targeting specific inflammatory pathways while preserving anti-cancer immune responses. Drugs that block specific cytokines or complement pathways may reduce thrombotic risk without compromising cancer treatment effectiveness.

Tocilizumab, an interleukin-6 receptor antagonist, is already used to treat cytokine release syndrome in CAR-T patients. Research is ongoing to determine whether this and similar drugs can also reduce thrombotic risk in other immunotherapy settings.

Personalized Risk Assessment

Advances in genomics and proteomics may allow for more personalized assessment of thrombotic risk in cancer patients. Genetic variants that affect drug metabolism, immune function, or clotting factor levels may help identify high-risk patients.

Biomarker panels that include inflammatory markers, coagulation factors, and immune activation markers may provide better risk stratification than current approaches. This could allow for more targeted prophylactic interventions in high-risk patients.

Novel Anticoagulants

New anticoagulant drugs specifically designed for cancer patients are in development. These agents aim to provide effective anticoagulation while minimizing bleeding risk and drug interactions common in cancer patients.

Some experimental approaches target specific pathways involved in cancer-associated thrombosis, such as tissue factor or neutrophil extracellular traps. These targeted approaches may be particularly relevant for patients receiving immunotherapy.

Real-World Evidence and Clinical Experience

Real-world studies of thrombosis in cancer patients receiving immunotherapy are providing valuable insights that complement clinical trial data. These studies often include more diverse patient populations and longer follow-up periods than controlled trials.

Registry studies have shown that thrombotic events in immunotherapy patients may have different patterns than those seen with traditional chemotherapy. For example, arterial events may be more common relative to venous events with certain checkpoint inhibitors.

A colleague recently shared an amusing observation from clinical practice that illustrates the complexity of managing these patients. A patient receiving checkpoint inhibitor therapy developed what appeared to be a pulmonary embolism on imaging, but further investigation revealed it was actually an unusual pattern of immune-related pneumonitis that mimicked a blood clot. The patient was initially started on anticoagulation before the correct diagnosis was made. This case highlights the importance of careful evaluation and the challenges in distinguishing between different complications in immunotherapy patients.

Quality of Life Considerations

Thrombotic events can have a major impact on quality of life for cancer patients. The need for long-term anticoagulation adds another layer of complexity to their treatment regimen. Patients must learn to manage medications, monitor for bleeding, and modify activities to reduce risk.

The psychological impact of thrombotic events should not be overlooked. Patients may develop anxiety about recurrent clots or bleeding complications. This can affect their willingness to continue cancer treatment or participate in normal activities.

Healthcare teams need to provide education and support to help patients manage these challenges. Clear communication about risks and benefits of different treatment options is essential for shared decision-making.

Economic Implications

The economic burden of thrombotic events in cancer patients is substantial. Hospitalizations for thrombosis treatment, long-term anticoagulation costs, and management of bleeding complications all contribute to healthcare expenses.

Immunotherapy drugs are expensive, and thrombotic complications may require treatment modifications or discontinuations that affect the cost-effectiveness of these treatments. Prevention strategies may be cost-effective if they reduce the need for hospitalization and emergency interventions.

Healthcare systems need to consider these economic factors when developing protocols for managing cancer patients receiving immunotherapy. Cost-effectiveness analyses can help guide decisions about prophylaxis and monitoring strategies.

Future Research Directions

Several areas of research are needed to better understand and manage thromboinflammation in cancer immunotherapy patients. Prospective studies are needed to define the true incidence and risk factors for thrombotic events with different immunotherapy regimens.

Mechanistic studies are needed to better understand how different immunotherapy agents affect blood clotting pathways. This knowledge could lead to more targeted prevention and treatment strategies.

Clinical trials are needed to evaluate different approaches to thrombosis prevention in immunotherapy patients. Current prevention strategies are largely based on studies in patients receiving traditional chemotherapy and may not be optimal for immunotherapy patients.

Research into biomarkers that can predict thrombotic risk in individual patients could enable more personalized approaches to prevention and monitoring. This could improve outcomes while reducing unnecessary treatments in low-risk patients.

Regulatory Considerations

Regulatory agencies are beginning to recognize the unique thrombotic risks associated with immunotherapy. Drug labels for some checkpoint inhibitors now include warnings about cardiovascular events, and post-marketing surveillance continues to monitor these risks.

Clinical trial designs for new immunotherapy agents should include careful monitoring for thrombotic events. This may require larger sample sizes or longer follow-up periods than traditional cancer drug trials.

Healthcare institutions are developing guidelines for monitoring and managing thrombotic risk in immunotherapy patients. These guidelines need to be based on emerging evidence and updated regularly as new data becomes available.

Global Perspectives

The management of thromboinflammation in cancer immunotherapy patients varies around the world due to differences in healthcare systems, drug availability, and clinical practices. Some countries have more extensive experience with certain immunotherapy agents, providing valuable insights for global practice.

International collaboration is important for advancing research in this field. Large, multi-center studies are needed to generate sufficient data to guide clinical practice. Harmonization of monitoring and management approaches could improve patient outcomes worldwide.

Resource-limited settings face particular challenges in managing these complex patients. Strategies for risk assessment and management need to be adapted to different healthcare environments and resource availability.

Education and Training

Healthcare providers caring for cancer patients receiving immunotherapy need education about thromboinflammation and its management. This includes recognition of symptoms, appropriate diagnostic testing, and treatment options.

Nursing staff play a crucial role in monitoring patients for signs of thrombotic events and educating patients about symptoms to watch for. Pharmacists can help with medication management and drug interaction screening.

Patient education is equally important. Patients need to understand their risk factors, recognize symptoms of thrombotic events, and know when to seek medical attention. Educational materials should be tailored to different patient populations and health literacy levels.

Challenges and Limitations

Several challenges limit our current understanding of thromboinflammation in cancer immunotherapy patients. Many studies have been retrospective or based on small patient numbers. Prospective, well-designed studies are needed but can be difficult to conduct due to the complexity of these patients.

The heterogeneity of cancer types, immunotherapy regimens, and patient populations makes it difficult to develop universal guidelines. Treatment recommendations may need to be tailored to specific patient groups or treatment combinations.

Distinguishing between thrombotic events related to immunotherapy versus those related to cancer or other factors can be challenging. This makes it difficult to determine the true attributable risk of different treatments.

The rapidly evolving field of immunotherapy means that new agents and combinations are constantly being developed. Research may not keep pace with clinical practice, leading to gaps in evidence-based management.

Best Practices and Recommendations

Based on current evidence and expert opinion, several best practices can be recommended for managing thrombotic risk in cancer immunotherapy patients. All patients should undergo careful risk assessment before starting treatment, including evaluation of cardiovascular risk factors and previous thrombotic events.

Baseline laboratory studies should include complete blood count, coagulation studies, and markers of inflammation. Patients at high risk may benefit from prophylactic anticoagulation, though the optimal approach is still being studied.

Regular monitoring during treatment should include assessment for symptoms and signs of thrombotic events. Healthcare providers should maintain a high index of suspicion, particularly in high-risk patients or those developing immune-related adverse events.

When thrombotic events occur, prompt diagnosis and treatment are essential. Treatment decisions should be individualized based on patient factors, event severity, and ongoing cancer treatment needs. Multidisciplinary consultation may be helpful for complex cases.

Key Takeaways

The relationship between thrombosis and cancer immunotherapy is complex and differs from traditional chemotherapy-associated thrombosis. Healthcare providers caring for immunotherapy patients need to understand these differences and adapt their monitoring and management strategies accordingly.

Risk assessment should be performed before starting immunotherapy and should include both traditional thrombotic risk factors and immunotherapy-specific considerations. High-risk patients may benefit from enhanced monitoring or prophylactic interventions.

Thrombotic events in immunotherapy patients may present differently than in other cancer patients. Maintaining a high index of suspicion and using appropriate diagnostic testing is essential for timely recognition and treatment.

Treatment of thrombotic events in immunotherapy patients requires individualized decision-making that considers multiple factors. Continuation of immunotherapy may be possible in some patients with appropriate anticoagulation.

Multidisciplinary care involving specialists in oncology, hematology, cardiology, and other fields may be beneficial for complex cases. Communication between team members is essential for optimal patient care.

Patient education about thrombotic risk and symptoms is an important component of care. Patients need to understand when to seek medical attention and how to manage their medications safely.

The field continues to evolve rapidly, and healthcare providers need to stay current with new research and guidelines. Professional development and continuing education are essential for providing optimal care.

Future research will likely provide better tools for risk assessment and more targeted prevention strategies. Healthcare providers should be prepared to adapt their practices as new evidence becomes available.

Frequently Asked Questions

What is the difference between thrombosis risk with immunotherapy compared to chemotherapy?

Immunotherapy may cause different patterns of thrombotic events compared to chemotherapy. While chemotherapy typically increases venous thromboembolism risk, some immunotherapy agents may preferentially increase arterial thrombotic events like heart attacks and strokes. The overall risk may be similar, but the types of events and their timing can differ.

Should all cancer patients receiving immunotherapy be on blood thinners?

Not all patients need prophylactic anticoagulation. The decision should be based on individual risk factors including age, cancer type, previous thrombotic events, and concurrent treatments. Current guidelines do not recommend universal prophylaxis for immunotherapy patients, but high-risk patients may benefit from prevention strategies.

How can physicians distinguish between thrombotic events and other immunotherapy side effects?

This can be challenging since symptoms may overlap. For example, shortness of breath could indicate pulmonary embolism or immune-related pneumonitis. Physicians need to maintain a high index of suspicion and use appropriate diagnostic testing including imaging studies and laboratory tests, while recognizing that some tests like D-dimer may be less reliable in cancer patients.

What should patients receiving immunotherapy know about thrombotic risk?

Patients should be aware of their individual risk factors and know the symptoms of blood clots to watch for. These include leg swelling or pain (deep vein thrombosis), chest pain or shortness of breath (pulmonary embolism), and symptoms of heart attack or stroke. They should seek immediate medical attention if these symptoms develop.

Can immunotherapy be continued after a thrombotic event?

This depends on several factors including the severity of the event, response to cancer treatment, and availability of alternative therapies. Some patients can safely continue immunotherapy with appropriate anticoagulation, while others may need treatment modifications or discontinuation. The decision should involve the entire healthcare team.

Are certain types of immunotherapy associated with higher thrombotic risk?

Different immunotherapy agents may have varying thrombotic risks. Some checkpoint inhibitors appear to increase arterial events more than venous events. CAR-T therapy can cause severe immune activation that affects blood clotting. However, more research is needed to fully characterize the risks of different agents.

How long do thrombotic risks persist after stopping immunotherapy?

The duration of increased thrombotic risk after immunotherapy is not well established. Some immune effects may persist for months after treatment discontinuation, but the specific impact on clotting risk is still being studied. Patients with ongoing risk factors may need continued monitoring and prevention strategies.

What monitoring is recommended for immunotherapy patients at risk for thrombosis?

Monitoring strategies are still evolving but may include regular assessment of symptoms, periodic laboratory studies, and imaging when indicated. High-risk patients may need more frequent monitoring. Healthcare providers should maintain good communication with patients about symptoms to watch for between visits.

References

Abdel-Razeq, H., Saadeh, S. S., Alakash, K., Khaled, L., Abdel-Razeq, R., & Kwok, G. (2021). Venous thromboembolism risk among cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. Cancer Treatment Reviews, 98, 102224.

Al-Samkari, H., Karp Leaf, R. S., Dzik, W. H., Carlson, J. C., Fogerty, A. E., Waheed, A., … & Bendapudi, P. K. (2018). COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, 136(4), 489-500.

Baden, M., Bianconi, V., Pirro, M., & Sahebkar, A. (2019). Immune checkpoint inhibitor-associated cardiovascular toxicity: A systematic review and meta-analysis. European Journal of Clinical Pharmacology, 75(8), 1063-1077.

Chen, D. S., & Mellman, I. (2017). Elements of cancer immunity and the cancer-immune set point. Nature, 541(7637), 321-330.

Conway, E. M. (2018). Reincarnation of ancient links between coagulation and complement. Journal of Thrombosis and Haemostasis, 16(3), 359-364.

D’Souza, P. C., Yeh, P., Mantha, S., & Shah, S. P. (2021). Arterial thrombotic events with immune checkpoint inhibitors: A systematic review. Seminars in Thrombosis and Hemostasis, 47(4), 866-875.

Falanga, A., Ay, C., Di Nisio, M., Gerotziafas, G., Jara-Palomares, L., Langer, F., … & Pabinger, I. (2021). Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 32(7), 860-873.

Franco, A. T., Corken, A., & Ware, J. (2015). Platelets at the interface of thrombosis, inflammation, and cancer. Blood, 126(5), 582-588.

Grover, S. P., & Mackman, N. (2018). Tissue factor: An essential mediator of hemostasis and trigger of thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 38(4), 709-725.

Haslam, A., & Prasad, V. (2019). Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Network Open, 2(5), e192535.

Icht, O., Darlyuk-Saadon, I., Levi-Barda, A., Mayer, S., Yarchovsky-Dolberg, O., Alpert, A., … & Ben-Betzalel, G. (2021). Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. Journal of Thrombosis and Haemostasis, 19(4), 1250-1258.

Jain, V., Bahia, J., Mohebtash, M., & Barac, A. (2021). Cardiovascular complications associated with novel cancer immunotherapies. Current Treatment Options in Cardiovascular Medicine, 23(5), 1-25.

Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., … & Moslehi, J. J. (2016). Fulminant myocarditis with combination immune checkpoint blockade. New England Journal of Medicine, 375(18), 1749-1755.

Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008). Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, 111(10), 4902-4907.

Larsen, J. B., Munkholm, S. H., Johnsen, S. P., Kristensen, S. R., & Grove, E. L. (2018). Temporal trends in the incidence of cancer-associated venous thromboembolism: A nationwide Danish cohort study. PloS One, 13(11), e0207656.

Lee, A. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., … & Clot Research Group. (2003). Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine, 349(2), 146-153.

Mahajan, A., Brunson, A., White, R., & Wun, T. (2021). The epidemiology of cancer-associated venous thromboembolism: An update. Seminars in Thrombosis and Hemostasis, 47(4), 387-398.

Mahé, I., Chidiac, J., Bertoletti, L., Font, C., Trujillo-Santos, J., Peris, M., … & RIETE Investigators. (2019). The clinical course of venous thromboembolism may differ according to cancer site. American Journal of Medicine, 132(5), 549-557.

Mauracher, L. M., Posch, F., Martinod, K., Grilz, E., Däullary, T., Hell, L., … & Ay, C. (2018). Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. Journal of Thrombosis and Haemostasis, 16(3), 508-518.

Mir, N., Huntington, S. F., Deng, Y., Marino, S., Zhou, Q., Zhao, H., & Davidoff, A. J. (2021). Hospitalization for venous thromboembolism in patients with hematologic malignancies in the era of novel therapeutics. Blood Advances, 5(4), 1009-1017.

Noble, S., Prout, H., & Nelson, A. (2015). Patients’ experiences of LIving with CANcer-associated thrombosis: The PELICAN study. Patient Preference and Adherence, 9, 337-345.

Nørøxe, D. S., Iqbal, O., Gulseth, H. L., Fareed, J., & Poulsen, L. H. (2021). Incidence of cancer-associated venous thromboembolism in relation to cancer stage and time since cancer diagnosis. Thrombosis Research, 197, 185-188.

Prandoni, P., Falanga, A., & Piccioli, A. (2005). Cancer and venous thromboembolism. The Lancet Oncology, 6(6), 401-410.

Rajkumar, T., Shpigel, A., Sison, C. P., Gajra, A., & Narayan, H. K. (2021). Venous thromboembolism and bleeding with cancer immunotherapy: Incidence and role of tumor type, immunotherapy agent, and coexisting comorbidities. European Journal of Haematology, 107(6), 618-629.

Riedl, J., Kaider, A., Reitter, E. M., Marosi, C., Jäger, U., Schwarzinger, I., … & Zielinski, C. (2017). Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Thrombosis and Haemostasis, 117(4), 670-678.

Russo, L., Ghaemi, S., Carpen, L., Galié, N., & Ghetti, G. (2021). Cardiac toxicity of immune checkpoint inhibitors: A systematic review. Heart Failure Reviews, 26(6), 1445-1459.

Salem, J. E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., … & Johnson, D. B. (2018). Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. The Lancet Oncology, 19(12), 1579-1589.

Sussman, T. A., Li, H., Hobbs, B., Funchain, P., McCrae, K. R., & Khorana, A. A. (2021). Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. Journal of Immunotherapy of Cancer, 9(1), e001719.

Thachil, J., & Lisman, T. (2020). Pulmonary embolism in COVID-19 patients: A clinical perspective. Thrombosis Research, 190, 58-59.

Timp, J. F., Braekkan, S. K., Versteeg, H. H., & Cannegieter, S. C. (2013). Epidemiology of cancer-associated venous thrombosis. Blood, 122(10), 1712-1723.

Verso, M., Agnelli, G., Barni, S., Gasparini, G., & LaBianca, R. (2012). A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The Protecht score. Internal and Emergency Medicine, 7(3), 291-292.

Weitz, I. C., Liebman, H. A., & Lal, I. (2021). Immune checkpoint inhibitor-associated thrombotic thrombocytopenic purpura. European Journal of Haematology, 106(5), 612-617.

Xu, Z., Zhu, Y., Wang, S., Ren, H., Omar, A. M., & Wilson, S. (2021). How checkpoint inhibitors cause cardiovascular toxicity: Evidence for systemic inflammatory response. Current Oncology Reports, 23(11), 1-12.

Zalpour, A., Sise, M. E., Sink, K. M., Shahzad, K., Rali, P., & Christie, J. (2019). Pulmonary hypertension due to checkpoint inhibitor therapy: A systematic review. Pulmonary Circulation, 9(2), 1-10.

Zhai, Z., Qi, X., Marchena, P. J., Johnson, E. S., Craig, A., Mu, G., … & Gersh, B. J. (2021). Venous thromboembolism risk factors in patients with cancer: A systematic review and meta-analysis. European Journal of Cancer, 144, 45-58.